Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL21855087 | 1.00 | SLC22A1 (0.55) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL1577204 | 1.00 | SLC22A1 (0.55) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL21855085 | 0.98 | SLC22A1 (0.52) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL21631807 | 0.98 | SLC22A1 (0.52) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL21545821 | 0.98 | SLC22A1 (0.52) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL28421584 | 0.98 | SLC22A1 (0.52) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL9723905 | 0.91 | SLC22A1 (0.50) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Tetrabuthylammonium SCHEMBL19834899 | 0.90 | SLC22A1 (0.48) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 | |
| Pyrophosphoric Acid SCHEMBL27668809 | 0.88 | FDPS (0.59) | LPAR3LPAR2LPAR1FDPSBLM | |
| Tetrabuthylammonium SCHEMBL21496366 | 0.88 | SLC22A1 (0.46) | SLC22A1LPAR3LPAR2LPAR1SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741406-A1 | NEUROKININ-1 RECEPTOR ANTAGONIST COMPOUND | Creadev (Nanjing) Pharmaceutical Technology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12522630-B2 | MRNA cap analog and uses thereof | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-01-13 | — | — | US | disclosed |
| US-20250257090-A1 | Ribonucleic Acids With 4'-Thio-Modified Nucleotides and Related Methods | TRANSLATE BIO, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250230183-A1 | MRNA CAP ANALOG AND USES THEREOF | HANMI FINE CHEMICAL CO., LTD. (KR) | 2025-07-17 | — | — | US | disclosed |
| WO-2025149479-A1 | SYNTHESIS OF MODIFIED NUCLEOSIDE TRIPHOSPHATES | ROCHE DIAGNOSTICS GMBH (DE) | 2025-07-17 | — | — | WO | disclosed |
| US-20250197820-A1 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-06-19 | — | — | US | disclosed |
| WO-2025071359-A1 | MRNA CAP ANALOG AND USE THEREOF | 한미정밀화학 주식회사 | 2025-04-03 | — | — | WO | disclosed |
| EP-4506353-A1 | MRNA CAP ANALOG AND USES THEREOF | Hanmi Fine Chemical Co., Ltd. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240327444-A1 | Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4399285-A2 | NUCLEIC ACID POLYMERASE AND ITS USE IN PRODUCING NON-DNA NUCLEOTIDE POLYMERS | United Kingdom Research and Innovation (GB) | 2024-07-17 | — | — | EP | disclosed |
| EP-1263752-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| US-6586461-B1 | Geranylgeranyl transferase inhibitors comprising farnesol and geranylgeraniol analogs, used as anticarcinogenic agents and for prevention of restenosis | WAYNE STATE UNIVERSITY | 2003-07-01 | — | — | US | disclosed |
| WO-2003024402-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
| EP-1263752-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002083720-A2 | INTERMEDIATES AND ENZYMES OF THE NON-MEVALONATE ISOPRENOID PATHWAY | BACHER ADELBERT (DE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2001071022-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6284910-B1 | FARNESYL TRANSFERASE INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2001-09-04 | — | — | US | disclosed |
| US-5668171-A | Halogenated mevalonate compositions and uses thereof in ras-dependent cell growth | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257090-A1 | Ribonucleic Acids With 4'-Thio-Modified Nucleotides and Related Methods | RNMT, RNGTT, NSUN3 | SLC22A1 2481/4885LPAR3 3252/4885LPAR2 3172/4885 |
| US-20250230183-A1 | MRNA CAP ANALOG AND USES THEREOF | RNGTT, RNMT, CAP1 | SLC22A1 2501/4885LPAR3 4202/4885LPAR2 4358/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | SLC22A1 2861/4885LPAR3 3/4885LPAR2 2/4885 |
| US-20240327444-A1 | Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate | NUDT1, SAMHD1, PNP | SLC22A1 1221/4885LPAR3 2353/4885LPAR2 2782/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | SLC22A1 3374/4885LPAR3 4/4885LPAR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.